Division of Sanofi
Latest From TargeGen Inc.
Investors in Impact Biosciences, which sold the selective JAK2 inhibitor to Celgene for $1.1bn up front, could double their money with milestone fees based on fedratinib's approval.
The latest drug development news and highlights from our US FDA Performance Tracker.
October was an active fundraising month for both start-up biopharma companies and more established privately held firms, ranging from $3m for Appili's drug for anaerobic infections to $270m for Harmony's rare disease programs.
Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Senior Management
Peter G Ulrich, Pres. & CEO
Wood C Erwin, VP, Fin. & CFO
Jolene Shorr, VP, Clin. Dev.
Forrest H Fuller, PhD, Sr. Dir., Bus. Dev.
- Contact Info
Phone: (858) 678-0760
9380 Judicial Dr.
San Diego, CA 92121
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.